// App-Quantinova.ai

13200 : Relationship Between Baseline Low-Density Lipoprotein Cholesterol and Percent Low-Density Lipoprotein Cholesterol Reduction With Evolocumab in the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) Trial

Researchers

Presenter

  • Dan P Marcusa

Principal Investigators

  • Robert P Giugliano

  • Jeong-Gun Park

  • Peter Sever

  • Huei Wang

  • Andrew Hamer

  • Terje R Pedersen

  • Anthony C Keech

  • Marc S Sabatine

Medical Centers

  • Brigham & Women's Hospital, Boston, MA

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • Imperial College, St. Mary's Campus, London, United Kingdom

  • AMGEN, Newbury Park, CA

  • Amgen Inc, Thousand Oaks, CA

  • Ulleval Univ Hosp, Oslo, Norway

  • NHMRC CLINICAL TRIALS CENTRE, Camperdown Sydney, Australia

  • TIMI Study Group, Boston, MA

Locations

  • United States

  • United Kingdom

  • Norway

  • Australia

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Coronary Artery Disease

Biomarkers

  • Cholesterol

  • Proprotein convertase subtilisin/kexin type 9

Drug/Treatment

  • Evolocumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved